Clinical study to further evaluate the efficacy of OncoGel based on overall tumor response at the primary tumor site

The purpose of this study is to determine the efficacy and safety of OncoGel treatment as an adjunctive therapy to systemic chemotherapy and concurrent external beam radiation prior to surgery in subjects with localized or loco-regional esophageal cancer. The treatment will be assigned randomly.

In order to participate you must have:

• Esophageal cancer
• Tumor must be T2-T3, N any, MO
• Tumor must be limited to the esophagus or the gastroesphageal junction
• Able to receive concurrent systemic chemotherapy (cisplatin and 5-FU) and RT

You will be excluded from the study if you:

• Had prior esophageal stent insertion, last or photodynamic therapy
• Prior chest RT or major esophageal surgery
• Any prior receipt of cytotoxic chemotherapeutic agents
• Prior receipt of other cancer treatments, vaccines or biological response modifiers/growth factors within the past four weeks

This is a partial list of eligibility criteria. To determine if you are eligible, please call the contact number provided above. If you choose to inquire via e-mail, please refer to the study title in your message.